PMID- 15692252 OWN - NLM STAT- MEDLINE DCOM- 20050321 LR - 20171101 IS - 1424-8832 (Print) IS - 1424-8832 (Linking) VI - 33 IP - 5-6 DP - 2003 Sep-2004 Dec TI - New developments in diagnosis and treatment of heparin-induced thrombocytopenia. PG - 407-12 AB - Heparin-induced thrombocytopenia (HIT) is a drug induced immune mediated thrombocytopenia that affects up to 3% of patients treated with unfractionated heparin (UFH). It is less frequent when low molecular weight heparins (LMWH) are used. Fondaparinux does not seem to induce HIT. A functional and an antigen assay should be performed to confirm the clinical diagnosis of HIT. Immediate cessation of heparin and start of compatible anticoagulant is mandatory when HIT is suspected clinically. Danaparoid (a heparinoid)and the direct thrombin inhibitors lepirudin and argatroban are available for this purpose. Short-term reexposure with heparin, for example during cardiopulmonary bypass, is possible in patients with history of HIT, provided HIT antiodies are no longer detectable. In children systematic data on treatment of HIT are lacking. FAU - Lubenow, Norbert AU - Lubenow N AD - Institut fur Immunologie und Transfusionsmedizin, Ernst-Moritz-Arndt-Universitat Greifswald, Germany. lubenow@uni-greifswald.de LA - eng PT - Journal Article PT - Review PL - Switzerland TA - Pathophysiol Haemost Thromb JT - Pathophysiology of haemostasis and thrombosis JID - 101142710 RN - 0 (Anticoagulants) RN - 9005-49-6 (Heparin) SB - IM MH - Anticoagulants/*adverse effects MH - Heparin/*adverse effects MH - Humans MH - Thrombocytopenia/chemically induced/*diagnosis/*drug therapy MH - Thrombosis/*drug therapy RF - 56 EDAT- 2005/02/05 09:00 MHDA- 2005/03/22 09:00 CRDT- 2005/02/05 09:00 PHST- 2005/02/05 09:00 [pubmed] PHST- 2005/03/22 09:00 [medline] PHST- 2005/02/05 09:00 [entrez] AID - 83837 [pii] AID - 10.1159/000083837 [doi] PST - ppublish SO - Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):407-12. doi: 10.1159/000083837.